Related Experiment Videos
N-acetyl muramyl dipeptide stimulation of bone resorption in tissue culture
Abstract:
N-Acetyl-muramyl-L-alanyl-D-isoglutamine (MDP), a structurally defined fragment of bacterial peptidoglycan, stimulated significant release of previously incorporated 45Ca from fetal rat bones in tissue culture over the concentration range of 0.1 to 10.0 micrograms/ml. MDP-Stimulated bone resorption was not inhibited by the addition of the prostaglandin synthetase inhibitor indomethacin to the culture medium. MDP was neither mitogenic for nor stimulated the release of osteoclast-activating factor from cultured human peripheral blood mononuclear cells. Thus, MDP-stimulated bone resorption in vitro is mediated by a mechanism which is not dependent upon prostaglandins or osteoclast-activating factor. 6-O-Stearoyl-N-acetyl-muramyl-L-alanyl-D-isoglutamine, a lipophilic analog of MDP, was slightly more potent than MDP. Two diastereomers of MDP, N-acetyl-muramyl-L-alanyl-L-isoglutamine and N-acetyl-muramyl-D-alanyl-D-isoglutamine, which are inactive as adjuvants, were at least 1,000 times less active than MDP in stimulating bone resorption. The stereochemical specificity for bone-resorptive activity paralleled that required for adjuvant activity, macrophage activation, and activation of the reticuloendothelial system.
Insights
N-Acetyl-muramyl-L-alanyl-D-isoglutamine (MDP), a bacterial peptidoglycan fragment, stimulates bone resorption in fetal rat bones. This effect is independent of prostaglandins and osteoclast-activating factor, highlighting a unique mechanism.
Area of Science:
- Immunology
- Bone Biology
- Microbiology
Background:
- Bacterial peptidoglycans are essential components of bacterial cell walls.
- N-Acetyl-muramyl-L-alanyl-D-isoglutamine (MDP) is a key structural fragment of peptidoglycans.
- Bone resorption is a critical process in skeletal remodeling and disease.
Purpose of the Study:
- To investigate the effect of MDP on bone resorption in vitro.
- To elucidate the mechanism underlying MDP-induced bone resorption.
- To assess the structure-activity relationship of MDP analogs in bone resorption.
Main Methods:
- Fetal rat bone cultures were used to measure 45Ca release.
- Prostaglandin synthetase inhibitor (indomethacin) was added to assess prostaglandin involvement.
- Human peripheral blood mononuclear cells were cultured to evaluate mitogenic effects and osteoclast-activating factor release.
Main Results:
- MDP significantly stimulated 45Ca release from fetal rat bones in a dose-dependent manner.
- Indomethacin did not inhibit MDP-stimulated bone resorption.
- MDP did not exhibit mitogenic activity or stimulate osteoclast-activating factor release.
- A lipophilic MDP analog showed slightly increased potency.
- Stereoisomers of MDP, inactive as adjuvants, were significantly less potent in stimulating bone resorption.
Conclusions:
- MDP-stimulated bone resorption in vitro is mediated by a mechanism independent of prostaglandins and osteoclast-activating factor.
- The stereochemical specificity of MDP's bone-resorptive activity is similar to its adjuvant activity.
- MDP represents a novel agent for studying bone resorption mechanisms.